Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 12/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 10/20 | 0.56 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.56 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.56 |
| ▸ | GCGR | P47871 | 9/20 | 0.56 |
| ▸ | GSK3B | P49841 | 3/20 | 0.56 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.56 |
| ▸ | FRK | P42685 | 2/20 | 0.56 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.56 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.56 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.56 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.56 |
| ▸ | BRAF | P15056 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7090083 | 0.89 | MAPK14 (0.65) | KDM4EHPGDSMN1; SMN2MAPK14MAPK13 | |
| SCHEMBL7083972 | 0.86 | PTGS2 (0.75) | SMN1; SMN2MAPK14MAPK11CSNK1A1CSNK1D | |
| SCHEMBL7087818 | 0.85 | ALOX5 (0.65) | KDM4EHPGDSMN1; SMN2MAPK14MAPK11 | |
| SCHEMBL15676793 | 0.85 | MAPK14 (0.50) | KDM4EHPGDSMN1; SMN2MAPK14MAPK13 | |
| SCHEMBL16713033 | 0.82 | KDM4E (0.44) | KDM4EHPGDSMN1; SMN2MAPK14MAPK13 | |
| SCHEMBL18041684 | 0.82 | TGFBR1 (0.53) | KDM4EHPGDSMN1; SMN2MAPK14MAPK13 | |
| SCHEMBL7041734 | 0.81 | KDM4E (0.67) | KDM4EHPGDSMN1; SMN2MAPK14MAPK13 | |
| SCHEMBL3371979 | 0.80 | MAPK14 (0.74) | KDM4EHPGDSMN1; SMN2MAPK14MAPK13 | |
| SCHEMBL1068923 | 0.80 | KDM4E (1.00) | KDM4EHPGDSMN1; SMN2MAPK14MAPK13 | |
| SCHEMBL18041867 | 0.80 | MAPK14 (0.54) | KDM4EHPGDSMN1; SMN2MAPK14MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39634-E1 | Bisarylimidazoly fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-15 | — | — | US | disclosed |
| US-RE39634-E1 | Bisarylimidazoly fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-15 | — | — | US | disclosed |
| US-RE39634-E1 | Bisarylimidazoly fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1389107-A4 | BISARYLIMIDAZOLYL FATTY ACID AMIDE HYDROLASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1389107-A1 | BISARYLIMIDAZOLYL FATTY ACID AMIDE HYDROLASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-02-18 | — | — | EP | disclosed |
| US-6562846-B2 | Bisarylimidazolyl fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-05-13 | — | — | US | disclosed |
| US-20020188009-A1 | Bisarylimidazolyl fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-12-12 | — | — | US | disclosed |
| WO-2002087569-A1 | BISARYLIMIDAZOLYL FATTY ACID AMIDE HYDROLASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188009-A1 | Bisarylimidazolyl fatty acid amide hydrolase inhibitors | FAAH, FAAH2, FASN | KDM4E 2584/4885HPGD 510/4885SMN1; SMN2 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.